comparemela.com

Latest Breaking News On - Forefront analytics - Page 12 : comparemela.com

Nkarta (NASDAQ:NKTX) Shares Gap Down to $11.09

Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $11.09, but opened at $10.80. Nkarta shares last traded at $10.82, with a volume of 70,617 shares trading hands. Analyst Upgrades and Downgrades Several analysts recently weighed in on the stock. Mizuho reduced their […]

Monaco
James-trager
Raymond-james
Paulj-hastings
Nasdaq
Acadian-asset-management
Forefront-analytics
Canaccord-genuity-group
Innovis-asset-management
Needham-company
Nkarta-inc
Prelude-capital-management

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $18.42 Average PT from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price […]

United-states
Stifel-nicolaus
Shelly-pinto
Jason-lettmann
Forefront-analytics
Nasdaq
Sg-americas-securities
Alx-oncology-holdings-inc
Hsbc-holdings
Jp-morgan-private-wealth-advisors
Oncology-holdings-inc
Jefferies-financial-group

Nkarta (NASDAQ:NKTX) Price Target Increased to $16.00 by Analysts at Canaccord Genuity Group

Nkarta (NASDAQ:NKTX – Get Free Report) had its price target increased by investment analysts at Canaccord Genuity Group from $15.00 to $16.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 52.53% from the stock’s previous […]

Monaco
Paulj-hastings
Raymond-james
James-trager
Prelude-capital-management
Nkarta-company-profile
Canaccord-genuity-group
Needham-company
Acadian-asset-management
Nkarta-inc
Forefront-analytics
Innovis-asset-management

Q1 2024 Earnings Forecast for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Issued By William Blair

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Equities research analysts at William Blair lifted their Q1 2024 EPS estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Thursday, March 21st. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of ($0.39) […]

Canada
United-states
Raymond-james
William-blair
Forefront-analytics
Eagle-health-investments
News-ratings-for-fusion-pharmaceuticals-daily
Hedge-funds-weigh-in-on-fusion-pharmaceuticals
Fusion-pharmaceuticals-stock
Fusion-pharmaceuticals
Fusion-pharmaceuticals-inc
Yarbrough-capital

Yarbrough Capital LLC Makes New $739,000 Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Yarbrough Capital LLC Makes New $739,000 Investment in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Canada
William-blair
Fusion-pharmaceuticals-profile
Exchange-commission
Citadel-advisors
Fusion-pharmaceuticals-inc
Fusion-pharmaceuticals
News-ratings-for-fusion-pharmaceuticals-daily
Schonfeld-strategic-advisors
Renaissance-technologies
Jefferies-financial-group
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.